Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV Compounds

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 677-687

  Kesisoglou, Filippos ^a   Mitra, Amitava ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioavailability enhancement; Nanocrystals; Nanoparticles; Nanosizing; Nanosuspensions

Indexed keywords

APREPITANT; CARBENDAZIM; CILOSTAZOL; DANAZOL; EFAVIRENZ; FENOFIBRATE; GRISEOFULVIN; MACROGOL 400; MEGESTROL ACETATE; NANOPARTICLE; POLYSORBATE 80; RAPAMYCIN;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CRYSTALLINE NANOSUSPENSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TOXICOLOGY;

EID: 84869118853     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9383-0     Document Type: Article

References (36)

1. Benet LZ, Wu CY. Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities. Somerset: NJDMDG; 2009.
2. Ku MS, Dulin W. A biopharmaceutical classification-based rightfirst-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-in-human to clinical proof-of-concept. Pharm Dev Technol. 2012; 17:285-302.
3. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18:113-20.
4. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-44.
5. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63:427-40.
6. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36:43-8.
7. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129-39.
8. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Topdown production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64-75.
9. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46:75-87.
10. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug adsorption: immediate release dosage forms. Pharm Res. 1998;15:11-22.
11. Mosharraf M, Nystrom C. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm. 1995;122:35-47.
12. Quinn K, Gullapalli RP, Merisko-Liversidge E, Goldbach E, Wong A, Liversidge GG, et al. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs. J Pharm Sci. 2012;101:1462-74.
13. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285:135-46.
14. Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol. J Pharm Pharm Sci. 2011;14 (2):196-214.
15. Nystrom C, Bisrat M. Physiochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm. 1998;47:223-31.
16. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm. 1998;160:229-37.
17. Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm. 2010;387:103-9.
18. Sugano K. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate druglike molecule population. Int J Pharm. 2009;373:55-61.
19. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res. 2008;25 (10):2302-8.
20. Kakran M, Shegokar R, Sahoo NG, Shaal LA, Li L, Müller RH. Fabrication of quercetin nanocrystals: comparison of different methods. Eur J Pharm Biopharm. 2012;80:113-21.
21. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56-64.
22. Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressmam JB. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm. 2010;76:95-104.
23. Jia L, Wong H, Wang Y, Garza M, Weitman SD. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci. 2003;92:161-72.
24. Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm. 2006;64:360-8.
25. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm. 2009;35:1479-86.
26. Euler D, Frech P, Karki S, Cowden C, Pearce G, Mehta P, et al. Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl) ethylamino)-6- chloropyrazin-2-one-1-Acetamide, a water insoluble thrombin inhibitor, in dog. Int J Pharm. 2004;275:19-27.
27. Jia L, Wong H, Cerna C, Weitman SD. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res. 2002;19:1091-6.
28. Kondo N, Iwao T, Masuda H, Yamanouchi K, Ishihara Y, Yamada N, et al. Improved oral absorption of a poorly watersoluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem Pharm Bull (Tokyo). 1993;41:737-40.
29. LiversidgeGG, CundyKC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91-7.
30. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, et al. Enhancement of oral bioavailability of an HIVattachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm. 2009;370:167-74.
31. Wyeth Pharmaceuticals, Inc.Rapamune(R) prescribing information. Philadelphia: Wyeth Pharmaceuticals; 2006.
32. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46:291-300.
33. Par Pharmaceutical Companies, Inc. Megace(R) ES prescribing information. Woodcliff: Par Pharmaceutical Companies; 2005.
34. Abbott Laboratories. Nanoparticle technology now allows TriCor(R) to be taken with or without food. Abbott Park: Abbott Laboratories; 2004.
35. Abbott Laboratories. TriCor(R) prescribing information. Abbott Park: Abbott Laboratories; 2004.
36. First Horizon Pharmaceutical Corporation. TriglideTM prescribing information. Roswell: First Horizon Pharmaceutical Corporation; 2005.